Tower Research Capital LLC TRC Has $54,000 Position in Annexon, Inc. (NASDAQ:ANNX)

Tower Research Capital LLC TRC lifted its position in shares of Annexon, Inc. (NASDAQ:ANNX) by 53.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,924 shares of the company’s stock after purchasing an additional 4,141 shares during the period. Tower Research Capital LLC TRC’s holdings in Annexon were worth $54,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ANNX. SG Americas Securities LLC bought a new position in Annexon during the third quarter worth about $52,000. Forefront Analytics LLC increased its holdings in shares of Annexon by 18.3% during the 3rd quarter. Forefront Analytics LLC now owns 31,680 shares of the company’s stock worth $75,000 after acquiring an additional 4,890 shares during the last quarter. Silverarc Capital Management LLC increased its holdings in shares of Annexon by 2.5% during the 3rd quarter. Silverarc Capital Management LLC now owns 399,716 shares of the company’s stock worth $943,000 after acquiring an additional 9,805 shares during the last quarter. Kennedy Capital Management LLC bought a new stake in Annexon in the 3rd quarter valued at $2,306,000. Finally, Sectoral Asset Management Inc. lifted its holdings in Annexon by 33.2% during the 3rd quarter. Sectoral Asset Management Inc. now owns 898,785 shares of the company’s stock valued at $2,121,000 after purchasing an additional 224,156 shares during the last quarter.

Annexon Price Performance

Shares of NASDAQ:ANNX remained flat at $4.70 on Monday. 1,627,200 shares of the company’s stock were exchanged, compared to its average volume of 1,527,537. Annexon, Inc. has a 1 year low of $1.57 and a 1 year high of $8.40. The company’s fifty day moving average price is $5.66 and its two-hundred day moving average price is $4.20. The firm has a market cap of $428.36 million, a P/E ratio of -2.64 and a beta of 1.14.

Annexon (NASDAQ:ANNX) last released its earnings results on Tuesday, March 26th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.09. Equities analysts predict that Annexon, Inc. will post -1.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Wells Fargo & Company upped their price objective on shares of Annexon from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Wednesday, March 27th. Bank of America upped their price target on shares of Annexon from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, March 28th. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Wednesday, April 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Annexon in a research report on Thursday, April 11th. Finally, JPMorgan Chase & Co. increased their target price on Annexon from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Monday, April 1st. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $14.43.

Insider Activity

In related news, CEO Douglas Love sold 5,782 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $5.54, for a total transaction of $32,032.28. Following the sale, the chief executive officer now owns 196,121 shares in the company, valued at approximately $1,086,510.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders sold 8,940 shares of company stock worth $49,514. 19.11% of the stock is currently owned by corporate insiders.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.